Drug intelligence / Profile preview

typhoid Vi polysaccharide vaccine

Development stage
Unknown
Lead developer
Finlay Vaccine Institute
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

vax-TyVi is a Vi polysaccharide vaccine developed by the Finlay Vaccine Institute for the prevention of typhoid fever. The vaccine is composed of the purified Vi capsular polysaccharide antigen extracted from *Salmonella enterica* serovar Typhi. Upon administration, it induces a T-cell independent immune response, stimulating the production of specific IgG antibodies against the Vi antigen, which provides protective immunity against infection. vax-TyVi is approved for use in adults and children (typically over two years of age) who are at risk of typhoid fever, particularly in endemic regions or for travelers.

Brand names
vax-TyVi
Other names
vax-TyVi vaccineFinlay typhoid vaccineTyphoid Vi polysaccharide vaccine
02

Targets

Vi polysaccharide-specific B-cell receptor

Beyond the preview

Go deeper on typhoid Vi polysaccharide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on typhoid Vi polysaccharide vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call